{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:13:23Z","timestamp":1780506803542,"version":"3.54.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Feline oral squamous cell carcinoma (OSCC) may cause painful bone destruction. Given the local invasiveness and rapid clinical progression of OSCC, conventional therapies are often palliative. In human cancer patients, zoledronate exerts anticancer effects by inhibiting tumor-induced angiogenesis and malignant osteolysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis<\/jats:title>\n                    <jats:p>Zoledronate will exert in vitro and in vivo anti-angiogenic and antiresorptive effects in feline OSCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Eight cats with OSCC were prospectively treated with zoledronate and conventional treatment modalities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In vitro, zoledronate's effects in modulating soluble vascular endothelial growth factor (VEGF) secretion and receptor activator of nuclear factor kB (NF-\u03baB) ligand (RANKL) expression were investigated in a feline OSCC cell line (SCCF1). In vivo, basal serum C-telopeptide (CTx) concentrations were compared among normal and OSCC-bearing cats, and the biologic effects of zoledronate administration in cats with naturally occurring OSCC were quantified by serially assessing circulating serum VEGF and CTx concentrations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In vitro, zoledronate concentrations greater than 3\u2003\u03bcM reduce soluble VEGF secretion in the SCCF1 cell line. The expression of RANKL in the SCCF1 cell line was also modulated by zoledronate, with low concentrations (3\u2003\u03bcM) decreasing but higher concentrations (30\u2003\u03bcM) increasing RANKL expression in comparison with untreated cells. In vivo, cats with bone-invasive OSCC had greater serum CTx concentrations in comparison with geriatric, healthy controls. Treatment with zoledronate rapidly decreased circulating serum VEGF and CTx concentrations in cats with spontaneously occurring OSCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Zoledronate exerts in vitro and in vivo effects that may favor the slowing of tumor growth and pathologic bone turnover associated with OSCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1939-1676.2007.0010.x","type":"journal-article","created":{"date-parts":[[2008,12,11]],"date-time":"2008-12-11T15:41:44Z","timestamp":1229010104000},"page":"158-163","source":"Crossref","is-referenced-by-count":32,"title":["In Vivo and In Vitro Efficacy of Zoledronate for Treating Oral Squamous Cell Carcinoma in Cats"],"prefix":"10.1093","volume":"22","author":[{"given":"J.M.","family":"Wypij","sequence":"first","affiliation":[{"name":"University of Illinois at Urbana-Champaign Comparative Oncology Research Laboratory, Department of Veterinary Clinical Medicine, , IL 61802"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.M.","family":"Fan","sequence":"additional","affiliation":[{"name":"University of Illinois at Urbana-Champaign Comparative Oncology Research Laboratory, Department of Veterinary Clinical Medicine, , IL 61802"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.L.","family":"Fredrickson","sequence":"additional","affiliation":[{"name":"University of Illinois at Urbana-Champaign Department of Pathology, , IL 61802"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Barger","sequence":"additional","affiliation":[{"name":"University of Illinois at Urbana-Champaign Department of Pathology, , IL 61802"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.P.","family":"De Lorimier","sequence":"additional","affiliation":[{"name":"University of Illinois at Urbana-Champaign Comparative Oncology Research Laboratory, Department of Veterinary Clinical Medicine, , IL 61802"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.C.","family":"Charney","sequence":"additional","affiliation":[{"name":"University of Illinois at Urbana-Champaign Comparative Oncology Research Laboratory, Department of Veterinary Clinical Medicine, , IL 61802"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2008,1,1]]},"reference":[{"key":"2026020304161564300_b1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0195-5616(03)00018-4","article-title":"Multimodality therapy for head and neck cancer","volume":"33","author":"Klein","year":"2003","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"2026020304161564300_b2","first-page":"670","article-title":"Tumors involving bone in the domestic cat","volume":"20","author":"Quigley","year":"1983","journal-title":"A review of fifty-eight cases"},{"key":"2026020304161564300_b3","first-page":"121","article-title":"Cat oral neoplasia","volume":"26","author":"Stebbins","year":"1989","journal-title":"A ten-year survey"},{"key":"2026020304161564300_b4","first-page":"777","article-title":"Treatment of mandibular squamous cell carcinoma in cats by use of mandibulectomy and radiotherapy","volume":"201","author":"Hutson","year":"1992","journal-title":"Seven cases (1987\u20131989)"},{"key":"2026020304161564300_b5","first-page":"350","article-title":"Outcomes of cats with oral tumors treated with mandibulectomy","volume":"42","author":"Northrup","year":"2006","journal-title":"42 cases"},{"key":"2026020304161564300_b6","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.2460\/javma.1993.202.11.1839","article-title":"Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors","volume":"202","author":"Ogilvie","year":"1993","journal-title":"J Am Vet Med Assoc"},{"key":"2026020304161564300_b7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1939-1676.1988.tb02794.x","article-title":"Efficacy and toxicity of doxorubicin and cyclophosphamide used in the treatment of selected malignant tumors in 23 cats","volume":"2","author":"Mauldin","year":"1988","journal-title":"J Vet Intern Med"},{"key":"2026020304161564300_b8","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2460\/ajvr.2000.61.791","article-title":"Use of cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II), a liposomal cisplatin analogue, in cats with oral squamous cell carcinoma","volume":"61","author":"Fox","year":"2000","journal-title":"Am J Vet Res"},{"key":"2026020304161564300_b9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1740-8261.2001.tb00907.x","article-title":"Response of cat oral squamous cell carcinoma to palliative radiation therapy","volume":"42","author":"Bregazzi","year":"2001","journal-title":"Vet Radiol Ultrasound"},{"key":"2026020304161564300_b10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.5326\/0390463","article-title":"Gemcitabine as a radiosensitizer for nonresectable cat oral squamous cell carcinoma","volume":"39","author":"Jones","year":"2003","journal-title":"J Am Anim Hosp Assoc"},{"key":"2026020304161564300_b11","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0360-3016(91)90012-S","article-title":"Technique, pharmacokinetics, toxicity, and efficacy of intratumoral etanidazole and radiotherapy for treatment of spontaneous cat oral squamous cell carcinoma","volume":"20","author":"Evans","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026020304161564300_b12","first-page":"466","article-title":"Unexpected toxicity following use of gemcitabine as a radiosensitizer in head and neck carcinomas","volume":"45","author":"LeBlanc","year":"2004","journal-title":"A veterinary radiation therapy oncology group pilot study"},{"key":"2026020304161564300_b13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"2026020304161564300_b14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/sonc.2002.37263","article-title":"Role of angiogenesis in tumor growth and metastasis","volume":"29","author":"Folkman","year":"2002","journal-title":"Semin Oncol"},{"key":"2026020304161564300_b15","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1242\/jcs.114.5.853","article-title":"The splice variants of vascular endothelial growth factor (VEGF) and their receptors","volume":"114","author":"Robinson","year":"2001","journal-title":"J Cell Sci"},{"key":"2026020304161564300_b16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4419-8871-3_1","article-title":"Vasculogenesis and angiogenesis","volume":"117","author":"Patan","year":"2004","journal-title":"Cancer Treat Res"},{"key":"2026020304161564300_b17","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1517\/14656566.6.10.1701","article-title":"Angiogenesis inhibitors in the treatment of cancer","volume":"6","author":"Rhee","year":"2005","journal-title":"Expert Opin Pharmacother"},{"key":"2026020304161564300_b18","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1634\/theoncologist.11-10-1121","article-title":"Bone loss and fracture risk associated with cancer therapy","volume":"11","author":"Guise","year":"2006","journal-title":"Oncologist"},{"key":"2026020304161564300_b19","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/jso.10067","article-title":"Immunohistochemical study of receptor activator of nuclear factor kappa-B ligand (RANK-L) in human osteolytic bone tumors","volume":"79","author":"Good","year":"2002","journal-title":"J Surg Oncol"},{"key":"2026020304161564300_b20","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1136\/jcp.55.11.877","article-title":"Tumour cells produce receptor activator of NF-kappaB ligand (RANKL) in skeletal metastases","volume":"55","author":"Huang","year":"2002","journal-title":"J Clin Pathol"},{"key":"2026020304161564300_b21","first-page":"6209s","article-title":"Advances in treating metastatic bone cancer","volume":"12","author":"Lipton","year":"2006","journal-title":"Summary statement for the First Cambridge Conference"},{"key":"2026020304161564300_b22","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res"},{"key":"2026020304161564300_b23","first-page":"295","article-title":"Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer","volume":"9","author":"Corey","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2026020304161564300_b24","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-03-0325","article-title":"Zoledronic acid inhibits visceral metastases in the 4T1\/luc mouse breast cancer model","volume":"10","author":"Hiraga","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2026020304161564300_b25","first-page":"482","article-title":"Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease","volume":"18","author":"Croucher","year":"2003","journal-title":"Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival"},{"key":"2026020304161564300_b26","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1172\/JCI200422087","article-title":"An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis","volume":"114","author":"Giraudo","year":"2004","journal-title":"J Clin Invest"},{"key":"2026020304161564300_b27","first-page":"84","article-title":"Cat head and neck squamous cell carcinoma","volume":"4","author":"Tannehill-Gregg","year":"2006","journal-title":"A natural model for the human disease and development of a mouse model"},{"key":"2026020304161564300_b28","first-page":"2893","article-title":"Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer cats","volume":"9","author":"Santini","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2026020304161564300_b29","first-page":"1262","article-title":"Bisphosphonates in prostate cancer","volume":"95","author":"Saad","year":"2003","journal-title":"Where are we and where should we go?"},{"key":"2026020304161564300_b30","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1089\/jir.2005.25.144","article-title":"Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer cats","volume":"25","author":"Vincenzi","year":"2005","journal-title":"J Interferon Cytokine Res"},{"key":"2026020304161564300_b31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000087286","article-title":"Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer cats","volume":"69","author":"Ferretti","year":"2005","journal-title":"Oncology"},{"key":"2026020304161564300_b32","first-page":"133","article-title":"Expression of receptor activator of nuclear factor kappa-B ligand (RANKL) in neoplasms of dogs and cats","volume":"21","author":"Barger","year":"2007","journal-title":"J Vet Intern Med"},{"key":"2026020304161564300_b33","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1292\/jvms.64.453","article-title":"Nucleotide sequence and expression of the cat vascular endothelial growth factor","volume":"64","author":"Koga","year":"2002","journal-title":"J Vet Med Sci"},{"key":"2026020304161564300_b34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.rvsc.2004.02.007","article-title":"A comparison of methods for measuring serum and urinary markers of bone metabolism in cats","volume":"77","author":"DeLaurier","year":"2004","journal-title":"Res Vet Sci"},{"key":"2026020304161564300_b35","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/j.1939-1676.2005.tb02790.x","article-title":"Bone metabolic effects of single-dose zoledronate in healthy dogs","volume":"19","author":"De Lorimier","year":"2005","journal-title":"J Vet Intern Med"},{"key":"2026020304161564300_b36","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.bbrc.2003.09.083","article-title":"A novel non-containing-nitrogen bisphosphonate inhibits both in vitro and in vivo angiogenesis","volume":"310","author":"Hamma-Kourbali","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"2026020304161564300_b37","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/cncr.11127","article-title":"Bone markers in the management of cats with skeletal metastases","volume":"97","author":"Demers","year":"2003","journal-title":"Cancer"},{"key":"2026020304161564300_b38","first-page":"335","article-title":"Urine N-telopeptide excretion in dogs with appendicular osteosarcoma","volume":"20","author":"Lacoste","year":"2006","journal-title":"J Vet Intern Med"},{"key":"2026020304161564300_b39","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1158\/1078-0432.CCR-06-0109","article-title":"Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers","volume":"12","author":"Rusk","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2026020304161564300_b40","first-page":"508","article-title":"Bisphosphonate-associated osteonecrosis","volume":"7","author":"Migliorati","year":"2006","journal-title":"A long-term complication of bisphosphonate treatment"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1939-1676.2007.0010.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/22\/1\/158\/66672042\/j.1939-1676.2007.0010.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/22\/1\/158\/66672042\/j.1939-1676.2007.0010.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T09:16:54Z","timestamp":1770110214000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/22\/1\/158\/8449819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1939-1676.2007.0010.x","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2008,1]]},"published":{"date-parts":[[2008,1,1]]}}}